Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Effectiveness of sitagliptin compared to sulfonylureas for type 2 diabetes mellitus inadequately controlled on metformin: a systematic review and meta-analysis.

Sharma M, Beckley N, Nazareth I, Petersen I.

BMJ Open. 2017 Oct 30;7(10):e017260. doi: 10.1136/bmjopen-2017-017260.

2.

Linagliptin versus sitagliptin in patients with type 2 diabetes mellitus: a network meta-analysis of randomized clinical trials.

Keshavarz K, Lotfi F, Sanati E, Salesi M, Hashemi-Meshkini A, Jafari M, Mojahedian MM, Najafi B, Nikfar S.

Daru. 2017 Oct 25;25(1):23. doi: 10.1186/s40199-017-0189-6. Review.

3.

Primary prevention of cardiovascular disease in older adults in China.

Yong J, Lin D, Tan XR.

World J Clin Cases. 2017 Sep 16;5(9):349-359. doi: 10.12998/wjcc.v5.i9.349. Review.

4.

Safety, Efficacy, and Bioavailability of Fixed-Dose Combinations in Type 2 Diabetes Mellitus: A Systematic Updated Review.

Vijayakumar TM, Jayram J, Meghana Cheekireddy V, Himaja D, Dharma Teja Y, Narayanasamy D.

Curr Ther Res Clin Exp. 2017 Feb 2;84:4-9. doi: 10.1016/j.curtheres.2017.01.005. eCollection 2017. Review.

5.

Dipeptidyl peptidase-4 inhibitors and the risk of heart failure: a systematic review and meta-analysis.

Verma S, Goldenberg RM, Bhatt DL, Farkouh ME, Quan A, Teoh H, Connelly KA, Leiter LA, Friedrich JO.

CMAJ Open. 2017 Feb 24;5(1):E152-E177. doi: 10.9778/cmajo.20160058. eCollection 2017 Jan-Mar.

6.

Effects of dipeptidyl peptidase-4 inhibitors on beta-cell function and insulin resistance in type 2 diabetes: meta-analysis of randomized controlled trials.

Lyu X, Zhu X, Zhao B, Du L, Chen D, Wang C, Liu G, Ran X.

Sci Rep. 2017 Mar 21;7:44865. doi: 10.1038/srep44865.

7.

Gemigliptin: An Update of Its Clinical Use in the Management of Type 2 Diabetes Mellitus.

Kim SH, Yoo JH, Lee WJ, Park CY.

Diabetes Metab J. 2016 Oct;40(5):339-353. Epub 2016 Sep 12. Review.

8.
9.

Incretin-Based Therapy and Risk of Pancreatic Cancer in Patients with Type 2 Diabetes Mellitus: A Meta-analysis of Randomized Controlled Trials.

Chen H, Zhou X, Chen T, Liu B, Jin W, Gu H, Hong T, Zhang G.

Diabetes Ther. 2016 Dec;7(4):725-742. Epub 2016 Sep 21.

10.

Differential HbA1c response in the placebo arm of DPP-4 inhibitor clinical trials conducted in China compared to other countries: a systematic review and meta-analysis.

He L, Liu S, Shan C, Tu Y, Li Z, Zhang XD.

BMC Pharmacol Toxicol. 2016 Sep 7;17(1):40. doi: 10.1186/s40360-016-0084-7. Review.

12.

Sitagliptin/metformin fixed-dose combination in type 2 diabetes mellitus: an evidence-based review of its place in therapy.

Hayes J, Anderson R, Stephens JW.

Drug Des Devel Ther. 2016 Jul 19;10:2263-70. doi: 10.2147/DDDT.S93076. eCollection 2016. Review.

13.

Randomized clinical trial of the safety and efficacy of sitagliptin and metformin co-administered to Chinese patients with type 2 diabetes mellitus.

Ji L, Han P, Wang X, Liu J, Zheng S, Jou YM, O'Neill EA, Golm GT, Engel SS, Kaufman KD, Shankar RR.

J Diabetes Investig. 2016 Sep;7(5):727-36. doi: 10.1111/jdi.12511. Epub 2016 May 19.

14.

Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studies.

Li L, Li S, Deng K, Liu J, Vandvik PO, Zhao P, Zhang L, Shen J, Bala MM, Sohani ZN, Wong E, Busse JW, Ebrahim S, Malaga G, Rios LP, Wang Y, Chen Q, Guyatt GH, Sun X.

BMJ. 2016 Feb 17;352:i610. doi: 10.1136/bmj.i610. Review.

15.

Efficacy, Safety and Treatment Satisfaction of Glimepiride vs Sitagliptin in Combination with Metformin in Type 2 Diabetes Mellitus.

Kumar S, Pathak AK, Saikia D, Kumar A.

J Clin Diagn Res. 2015 Dec;9(12):FC07-10. doi: 10.7860/JCDR/2015/17027.6888. Epub 2015 Dec 1.

16.

Systematic review and meta-analysis of efficacy and safety of combinational therapy with metformin and dipeptidyl peptidase-4 inhibitors.

Alanazi AS.

Saudi Pharm J. 2015 Nov;23(6):603-13. doi: 10.1016/j.jsps.2013.12.018. Epub 2014 Jan 3. Review.

17.

Apparent subadditivity of the efficacy of initial combination treatments for type 2 diabetes is largely explained by the impact of baseline HbA1c on efficacy.

Polidori D, Capuano G, Qiu R.

Diabetes Obes Metab. 2016 Apr;18(4):348-54. doi: 10.1111/dom.12615. Epub 2016 Jan 25.

18.

Clinical Characteristics and Metabolic Predictors of Rapid Responders to Dipeptidyl Peptidase-4 Inhibitor as an Add-on Therapy to Sulfonylurea and Metformin.

Kim YA, Yoo WS, Hong ES, Ku EJ, Park KS, Lim S, Cho YM, Park KS, Jang HC, Choi SH.

Diabetes Metab J. 2015 Dec;39(6):489-97. doi: 10.4093/dmj.2015.39.6.489. Epub 2015 Nov 27.

19.

Antidiabetic treatment with gliptins: focus on cardiovascular effects and outcomes.

Fisman EZ, Tenenbaum A.

Cardiovasc Diabetol. 2015 Sep 29;14:129. doi: 10.1186/s12933-015-0294-0. Review.

20.

Effects of Sitagliptin on Insulin and Glucagon Levels in Type 2 Diabetes Mellitus.

Kim JH.

Diabetes Metab J. 2015 Aug;39(4):304-6. doi: 10.4093/dmj.2015.39.4.304. No abstract available.

Supplemental Content

Support Center